These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21470374)

  • 1. Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.
    Curtis J; Henry C; Watkins A; Newall H; Samaras K; Ward PB
    Early Interv Psychiatry; 2011 May; 5(2):108-14. PubMed ID: 21470374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic risk factors in drug-naive patients with first-episode psychosis.
    Verma SK; Subramaniam M; Liew A; Poon LY
    J Clin Psychiatry; 2009 Jul; 70(7):997-1000. PubMed ID: 19497246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
    Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
    Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis.
    Thompson A; Hetrick SE; Alvarez-Jiménez M; Parker AG; Willet M; Hughes F; Gariup M; Gomez DL; McGorry PD
    Aust N Z J Psychiatry; 2011 Sep; 45(9):740-8. PubMed ID: 21827345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.
    Verma S; Liew A; Subramaniam M; Poon LY
    Aust N Z J Psychiatry; 2009 Sep; 43(9):812-7. PubMed ID: 19670054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain--as possible predictor of metabolic syndrome.
    Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study.
    Bai YM; Lin CC; Chen JY; Chen TT; Su TP; Chou P
    J Clin Psychiatry; 2011 Jun; 72(6):751-6. PubMed ID: 21208584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
    Britvic D; Maric NP; Doknic M; Pekic S; Andric S; Jasovic-Gasic M; Popovic V
    Psychiatr Danub; 2013 Dec; 25(4):410-5. PubMed ID: 24247054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The heart of the matter: cardiometabolic care in youth with psychosis.
    Curtis J; Newall HD; Samaras K
    Early Interv Psychiatry; 2012 Aug; 6(3):347-53. PubMed ID: 22221395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis.
    Batscha C; Schneiderhan ME; Kataria Y; Rosen C; Marvin RW
    J Psychosoc Nurs Ment Health Serv; 2010 Sep; 48(9):44-9. PubMed ID: 20795590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme.
    Barnes TR; Paton C; Hancock E; Cavanagh MR; Taylor D; Lelliott P;
    Acta Psychiatr Scand; 2008 Jul; 118(1):26-33. PubMed ID: 18582345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of the metabolic syndrome and its influencing factors among adolescent girls in Mashhad, Iran.
    Mirhosseini NZ; Yusoff NA; Shahar S; Parizadeh SM; Mobarhen MG; Shakery MT
    Asia Pac J Clin Nutr; 2009; 18(1):131-6. PubMed ID: 19329406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: preliminary study].
    Diurni M; Baranzini F; Costantini C; Poloni N; Vender S; Callegari C
    Recenti Prog Med; 2009 Feb; 100(2):103. PubMed ID: 19350804
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands.
    Schorr SG; Slooff CJ; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2009 Aug; 29(4):399-402. PubMed ID: 19593188
    [No Abstract]   [Full Text] [Related]  

  • 18. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A specialist early intervention for first-episode psychosis.
    Singh SP; Fisher HL
    Psychiatr Serv; 2004 Aug; 55(8):942-3. PubMed ID: 15292549
    [No Abstract]   [Full Text] [Related]  

  • 20. Open-label pilot study on vitamin D₃ supplementation for antipsychotic-associated metabolic anomalies.
    Thakurathi N; Stock S; Oppenheim CE; Borba CP; Vincenzi B; Seidman LJ; Stone WS; Henderson DC
    Int Clin Psychopharmacol; 2013 Sep; 28(5):275-82. PubMed ID: 23694999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.